RxDoctor Payments Data

David Willms, MD

Pulmonary Disease · San Diego, CANPI 1285626747

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $40,849 of the $47,492 with a category attached, or 86.0%. La Jolla Pharmaceutical Company accounts for 84.5% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $14,032 and has fallen 80.8% since, to $2,691 in 2025. Among pulmonary disease clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$47,492in general payments, 2019–2025

Across 64 payments — averaging $742.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • La Jolla Pharmaceutical Company$40K
  • Portola Pharmaceuticals, LLC$3K
  • BTG International Inc.$2K
  • BD$1K
  • Inari Medical, Inc.$172
  • Abiomed$126
  • plus $467 from 6 others

What the payments were for

  • Consulting fees$3,1757%
  • Speaking & faculty fees$40,84986%
  • Travel & lodging$1,1362%
  • Food & beverage$2,3315%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$47,492 in reported general payments places this provider in the 90th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California →

Medicare billing

Part B allowed, 2024
$287,071
Medicare patients
280
Services billed
2,840

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ipratropium-AlbuterolIpratropium/Albuterol Sulfate31$597

Paid to pharmacies, not to this prescriber.

Other pulmonary disease in San Diego

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →